Ananda Pharma (STU:1FX) Graham Number: €N/A (As of Jul. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Ananda Pharma Graham Number?

Ananda Pharma STU:1FX Graham Number is €N/A as of Jul. 2025. The stock has 5 warning signs investors should review. Among 600 Drug Manufacturers companies, Ananda Pharma ranks worse than 166666.5% on this metric.

Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.

As of today (2026-08-20), the stock price of Ananda Pharma is €0.0005. Ananda Pharma's graham number for the quarter that ended in Jul. 2025 was €N/A. Therefore, Ananda Pharma's Price to Graham Number ratio for today is N/A.

The historical rank and industry rank for Ananda Pharma's Graham Number or its related term are showing as below:

STU:1FX's Price-to-Graham-Number is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.58
* Ranked among companies with meaningful Price-to-Graham-Number only.

Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.


Ananda Pharma  (STU:1FX) Graham Number Explanation

Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:

Current price should not be more than 15 times average earnings of the past three years.

Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)

Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.

In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.

Ananda Pharma's Price to Graham number Ratio for today is calculated as

Price to Graham number=Share Price (Today)/Graham number (Q: Jul. 2025 )
=0.0005/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Please keep these in mind:

1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.


Ananda Pharma Graham Number Related Terms


Ananda Pharma Graham Number Historical Data

* Premium members only.

The historical data trend for Ananda Pharma's Graham Number can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ananda Pharma Graham Number Chart

Ananda Pharma Annual Data
Trend Jan19 Jan20 Jan21 Jan22 Jan23 Jan24 Jan25
Graham Number
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Ananda Pharma Semi-Annual Data
Jul18 Jan19 Jul19 Jan20 Jul20 Jan21 Jul21 Jan22 Jul22 Jan23 Jul23 Jan24 Jul24 Jan25 Jul25
Graham Number Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:1FX vs ZTS, UTHR, VTRS: Graham Number Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ananda Pharma's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ananda Pharma Price-to-Graham-Number vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ananda Pharma's Price-to-Graham-Number distribution charts can be found below:

* The bar in red indicates where Ananda Pharma's Price-to-Graham-Number falls into.



Ananda Pharma Graham Number Calculation

Graham Number is a concept based on Ben Graham's conservative valuation of companies.

Ananda Pharma's Graham Number for the fiscal year that ended in Jan. 2025 is calculated as

Graham Number
=sqrt of (22.5* Tangible Book per Share *EPS without NRI)
=sqrt of (22.5*0*-0.001)
=N/A

Ananda Pharma's Graham Number for the quarter that ended in Jul. 2025 is calculated as

Graham Number
=sqrt of (22.5*Tangible Book per Share*EPS without NRI (TTM))
=sqrt of (22.5*-0*-0.002)
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Graham Number →
What does a Graham Number of €N/A mean?
Ananda Pharma (STU:1FX) has a Graham Number of €N/A as of Jul. 2025. The Graham Number values a company based on its per-share earnings and book value. View historical data on Ananda Pharma and its competitors. According to the industry distribution chart, Ananda Pharma ranks #999999 out of 600 companies in the Drug Manufacturers industry.
Is Ananda Pharma's Graham Number too high?
Ananda Pharma's current Graham Number is €N/A. Based on the distribution chart, Ananda Pharma ranks #999999 out of 600 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Ananda Pharma's Graham Number compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ananda Pharma ranks #999999 out of 600 companies for Graham Number. This places Ananda Pharma in the lower half of its industry. The industry median Graham Number is 1.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Drug Manufacturers company?
The median Graham Number among Drug Manufacturers companies is 1.58, based on 600 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on Ananda Pharma and its competitors. For the Drug Manufacturers industry, the median Graham Number is 1.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ananda Pharma's current Graham Number is €N/A. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ananda Pharma stock overvalued right now?
Ananda Pharma (STU:1FX) has a current Graham Number of €N/A. The current Graham Number is €N/A. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For Ananda Pharma (STU:1FX), the current Graham Number is €N/A as of Jul. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ananda Pharma Business Description

Address 60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Ananda Pharma PLC is a UK-based biopharmaceutical company developing regulatory-approved, cannabidiol medicines to treat complex, chronic conditions, including endometriosis (funded by NHS Scotland) and chemotherapy-induced peripheral neuropathy (funded by NIHR).